中华肝脏病杂志最新文献

{"title":"[Focus on schistosomiasis cirrhosis: disease burden, pathogenic characteristics, and research frontiers].","authors":"X He, J P Zhao, Q Chen, C Su, X P Chen","doi":"10.3760/cma.j.cn501113-20250507-00174","DOIUrl":"10.3760/cma.j.cn501113-20250507-00174","url":null,"abstract":"<p><p>Schistosomiasis cirrhosis (SAC), as the core pathological outcome of late-stage schistosomiasis, is an important challenge to global public health. Notably, there is still a significant disease burden, especially in the traditional endemic areas, such as the Yangtze River Basin in China. SAC has unique pathogenic characteristics, including insect-derived molecular-driven disease, chronic inflammation dominated by Th2 immunity, delayed pathogenicity, noticeable symptoms of portal hypertension, and an absence of significant correlation with liver cancer. Therefore, future research should focus on the determinants of individual susceptibility to SAC onset, the core mechanism of liver lesion progression post-pathogen clearance, time nodes, and intervention methods. Additionally, finding the high-risk individuals, analyzing of pathological mechanisms, and optimizing intervention strategies will help in promoting the development of clinical prevention and control and translational research.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 5","pages":"412-415"},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A case of type 4A familial hereditary hemochromatosis].","authors":"K F Wang, W Hou, W Y Song, H Liu, S J Zheng","doi":"10.3760/cma.j.cn501113-20241202-00607","DOIUrl":"10.3760/cma.j.cn501113-20241202-00607","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 5","pages":"489-492"},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Prioritize a multidisciplinary approach to the diagnosis and management of portal hypertension].","authors":"Z G Zhang, X P Chen","doi":"10.3760/cma.j.cn501113-20250512-00184","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20250512-00184","url":null,"abstract":"<p><p>Portal hypertension primarily arises from chronic liver disease, which seriously affects people's lives and health, and its treatment has always been considered complex and diverse. With the innovation of ideas and technologies, its treatment model has transitioned from unidisciplinary to multidisciplinary collaborative diagnosis and treatment. The treatment of portal hypertension tends to be more individualized, standardized, and minimally invasive under the multidisciplinary diagnosis and treatment model. Furthermore, the greatest extent of therapeutic effect for portal hypertension can be optimized by multidisciplinary collaboration and selection of individualized diagnosis and treatment methods for different populations. Therefore, it is imperative to diagnose and treat portal hypertension propensity in a multidisciplinary collaboration.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 5","pages":"409-411"},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress on new drugs for the treatment of chronic hepatitis B virus infection].","authors":"Y Y Yu, J Li, W X Wang, P Y Fan, F S Wang","doi":"10.3760/cma.j.cn501113-20240521-00258","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240521-00258","url":null,"abstract":"<p><p>Hepatitis B virus (HBV) infection is a major global public health problem. There will be about 257 million chronic HBV-infected patients worldwide, according to the World Health Organization's estimation by 2025. Currently, the main drugs for the treatment of chronic HBV infection are nucleos(t)ide analogues and pegylated interferon (PEG-IFN). However, previous research results show that whether it is nucleos(t)ide analogues and PEG-IFN-α monotherapy or combination therapy, or sequential combination therapy, the rate of hepatitis B surface antigen seroconversion in patients is low, and there is still a high risk of disease progression after a certain course of antiviral treatment. Therefore, to achieve the ambitious target of \"eliminating viral hepatitis by 2030\" set by the World Health Organization and help more hepatitis B patients achieve functional cure, a large number of new drugs have been developed and entered clinical trials. This paper summarizes and reviews the types, safety, and efficacy of new drugs to further promote advancements in the field of treatment of chronic HBV infection.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 5","pages":"493-499"},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Sulfasalazine relieves cholestatic liver injury by activating peroxisome proliferator-activated receptor-α].","authors":"J Xu, X Wang, Y Zhang, J Xiao, H You, Z Y Liu, Y Sun, Y H Lan, H Ren, C G Liu, M L Peng","doi":"10.3760/cma.j.cn501113-20250124-00041","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20250124-00041","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the efficacy and potential mechanism of sulfasalazine (SASP) therapy for intrahepatic cholestasis. &lt;b&gt;Methods:&lt;/b&gt; Forty SD rats were randomly divided into a normal group (carboxymethylcellulose sodium 0.5%), a model group (carboxymethylcellulose sodium 0.5%), a SASP group (sulfasalazine 150 mg/kg), and an ursodeoxycholic acid (UDCA 100 mg/kg) group, with ten rats in each group. The cholestatic liver injury model was induced using α-naphthylisothiocyanate. Blood samples were collected to detect liver biochemistry and cholestasis indexes. Rat liver tissue was collected for hematoxylin-eosin staining and Mason staining. Liver tissue was analyzed using transcriptome sequencing, real-time reverse transcription quantitative polymerase chain reaction, Western blotting and flow cytometry. Simultaneously, the level of inflammatory factors, total cholesterol, and total bile acids were measured in liver tissue. A &lt;i&gt;t&lt;/i&gt;-test or a nonparametric test was selected based on the distribution and variance characteristics of the data. &lt;b&gt;Results:&lt;/b&gt; The serum levels of alanine aminotransferase [(386.88±155.77) U/L], aspartate aminotransferase [(593.13±251.44) U/L], alkaline phosphatase [(561.25±167.54) U/L], total bilirubin [(38.00±29.75) mol/L] and total bile acids [(191.31±91.48) mol/L] were significantly lower in the SASP than the model groups [(778.75±313.59) U/L, (1 159.38±274.62) U/L, (801.25±161.28) U/L, (86.63±27.83) mol/L, (432.63±151.54) mol/L,&lt;i&gt;P&lt;/i&gt;&lt;0.05]. Liver histopathology showed that the inflammatory cells in the manifold area, the bile duct proliferation and dilation, and the collagen deposition in the manifold area were significantly improved under the pathological state of cholestasis in the SASP group. The results of transcriptome sequencing demonstrated that SASP activated the peroxisome proliferator actived receptor &lt;i&gt;α&lt;/i&gt; (PPAR&lt;i&gt;α&lt;/i&gt;) and inhibited Th17 cell differentiation. The &lt;i&gt;PPARα&lt;/i&gt; mRNA level in the liver tissue of rats was significantly increased in the SASP group compared with that in the model group [(0.41±0.28) &lt;i&gt;vs&lt;/i&gt;. (0.16±0.04), &lt;i&gt;P&lt;/i&gt;&lt;0.05], and the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase was decreased compared with that in the model group [(3.09±1.16) &lt;i&gt;vs&lt;/i&gt;. (8.19±2.19), &lt;i&gt;P&lt;/i&gt;&lt;0.05], which was also verified at the protein level. The concentrations of total cholesterol [(0.31±0.34) mmol/g] and total bile acids [(2.58±0.99) μmol/g] were lower than the model group [(0.83±0.62) mmol/g and (4.07±0.91) μmol/g] (&lt;i&gt;P&lt;/i&gt;&lt;0.05), and at the same time it was accompanied by lower levels of inflammatory factors (&lt;i&gt;P&lt;/i&gt;&lt;0.05). SASP treatment decreased the expression of retinoic acid receptor-related orphan receptor γt gene (&lt;i&gt;P&lt;/i&gt;&lt;0.05) and the proportion of Th17 (&lt;i&gt;P&lt;/i&gt;&lt;0.05). &lt;b&gt;Conclusion:&lt;/b&gt; SASP can improve cholestatic liver injury, and its mechanism is related to the activation of peroxisome proliferator-activated receptor α and the inhibiti","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 5","pages":"448-455"},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress on predictive indicators of a clinical cure for chronic hepatitis B].","authors":"R Y Zhang, W Yue, L Zhu, J B Luo, B Bu, Y L Wang, Y M Wang, J W Geng","doi":"10.3760/cma.j.cn501113-20241015-00541","DOIUrl":"10.3760/cma.j.cn501113-20241015-00541","url":null,"abstract":"<p><p>Nucleotide analogues (NAs) and interferon are still the first-line drugs for the treatment of chronic hepatitis B (CHB), but they still cannot completely eliminate covalently closed circular DNA (cccDNA) within hepatocytes. The clinical cure, or the disappearance of HBsAg, is the ideal goal of antiviral therapy. Although interferon therapy has a significantly greater HBsAg clearance rate and seroconversion rate than NAs, combination or sequential treatment can improve the HBsAg clearance rate and seroconversion rate to a certain extent, and only a small proportion of CHB patients can achieve clinical cure. Therefore, finding indications that predict clinical cure before and during antiviral treatment is crucial for identifying patients who are more likely to achieve HBsAg clearance at an early stage, improving clinical cure rates, and reducing treatment costs. This article reviews the research progress on predictive indicators of clinical cure of chronic hepatitis B in the past five years, explores the value of each indicator in predicting clinical cure, and provides a reference for optimizing CHB treatment strategies.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 ","pages":"500-504"},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[An excerpt of European Association for the Study of the Liver clinical practice guidelines on transjugular intrahepatic portosystemic shunt in 2025].","authors":"Z Y Wang, G H Han","doi":"10.3760/cma.j.cn501113-20250418-00148","DOIUrl":"10.3760/cma.j.cn501113-20250418-00148","url":null,"abstract":"<p><p>Transjugular intrahepatic portosystemic shunt (TIPS) is a proven procedure therapy for complications in cirrhotic portal hypertension (PH). In recent years, there has been a lot of progress in the field of TIPS, especially in terms of technical operation, prognostic models, and indication expansion. Therefore, the guidelines aim to provide a comprehensive overview of all aspects of the use of TIPS in patients with cirrhosis while separating sections pertaining to other specialized subjects (e.g., the usage of TIPS in surgical procedures and hepatovascular disorders).</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 5","pages":"434-439"},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research advances in occurrence risk assessment and early-stage diagnosis of hepatocellular carcinoma].","authors":"Y J Li, J F Li, Y Chen","doi":"10.3760/cma.j.cn501113-20231124-00231","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20231124-00231","url":null,"abstract":"<p><p>Evaluating and identifying the occurrence risk of hepatocellular carcinoma (HCC) can make the gateway for prevention and diagnosis advance as well as assist in the early detection and intervention of future HCC occurrences within the population. Early-stage diagnosis and treatment are crucial for improving survival rates in patients with HCC. This article reviews the recent years' research progress in terms of combining three aspects-molecular markers, scoring models, and early-stage diagnostics-to predict the evaluation of HCC occurrence risk, with the hope of providing guiding significance for clinical practice.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 5","pages":"505-510"},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A case of cavernous transformation of the portal vein treated with transjugular intrahepatic portosystemic shunt assisted by implementing cannulation of the superior mesenteric vein branch].","authors":"Y Zhang, Y F Wu, C B Dong, Q M Li, Z H Fan, Z D Yue, G Z Xu, D Z Wang, L Wang","doi":"10.3760/cma.j.cn501113-20240510-00247","DOIUrl":"10.3760/cma.j.cn501113-20240510-00247","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 4","pages":"379-382"},"PeriodicalIF":0.0,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144152068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A case of congenital hepatic fibrosis accompanied with multiple system abnormalities].","authors":"T F Liu, Y Kong, L Y Zhang, L Wang","doi":"10.3760/cma.j.cn501113-20240122-00049","DOIUrl":"10.3760/cma.j.cn501113-20240122-00049","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 4","pages":"383-387"},"PeriodicalIF":0.0,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144152071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}